Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Neoplasms | 1 |
Immune System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
CFD(Complement factor D) | 1 |
Target |
Mechanism CFD inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date18 Jan 2024 |
Target |
Mechanism CFD inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NS3/NS4A inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Dec 2019 |
Sponsor / Collaborator |
Start Date28 Jul 2019 |
Sponsor / Collaborator |
Start Date31 Jan 2019 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Vemircopan ( CFD ) | Autoimmune Diseases More | Phase 1 |
Odalasvir ( NS5A ) | Hepatitis C More | Discontinued |
ACH-2928 ( Hepatitis C virus NS 5 protein ) | Hepatitis C More | Discontinued |
Danicopan ( CFD ) | Hemolytic-Uremic Syndrome More | Discontinued |
Sovaprevir ( NS3/NS4A ) | Hepatitis C More | Discontinued |